BIO CEO on Leave After Drug Pricing Reform and Industry Setbacks

Michelle McMurry-Heath, CEO of BIO is currently on leave following a tumultuous two-year term that was beset by the pandemic, a chaotic biotech market, and the passage of drug pricing reform by the US government. BIO had spent years lobbying alongside other industry groups against such regulations to no avail with the Biden Administration’s landmark Inflation Reduction Act.

According to John Carroll, “When she joined BIO in the summer of 2020, McMurry-Heath was hailed as a physician and scientist who was “the right person at the right time to lead us into the future.” She had held a senior post at J&J which included a regulatory role following a job at the FDA. She was also the first Black graduate from Duke’s medical scientist training program.”

To read more, click here.

(Source: Endpoints News, October 9^th, 2022)